Aim: The intent of present work was concerned with formulation and evaluation of bioadhesive buccal drug delivery of lesinurad tablets, which is plenteously metabolized by liver and avoiding first pass metabolism and prolonging duration of action. Lesinurad is a urate transporter inhibitor for treating hyperuricemia associated with gout. Materials and Methods: Lesinurad tablets were prepared by direct compression method using bioadhesive polymers such as hydroxypropyl methylcellulose K 200M, Carbopol 940 and sodium alginate in different ratios and ethylcellulose as backing layer. The formulations were characterized for physiochemical parameters, in vitro release studies The physicochemical compatibility of drug and polymers was studied by FT–IR spectroscopy. Results and Discussion: The formulations were tested for bioadhesive strength, ex vivo residence time, swelling time and in vitro dissolution studies and ex vivo permeation studies, bioadhesive strength, surface PH. Optimized formulation (F8) showed 92 % in vitro release in 8 h and 65.8% permeation of drug through porcine buccal mucosa and followed fickian release mechanism with zero order kinetics. This product was more comfortable to the user due to absence of erosion, faster hydration rate and less viscosity of surrounding environment FTIR studies of optimized formulation showed no evidence of interaction between the drug and polymers. To conclude that the formulated unidirectional, bilayered, bioadhesive buccal tablet for lesinurad using HPMC as mucoadhesive agent is superior to oral conventional tablets, as it has the potential to bypass the first pass metabolism and improve the bioavailability of lesinurad. In vivo mucoadhesive behaviour of optimized formulation was performed and parameters were evaluated.